Most heterozygous carriers of CYP24A1 mutations do not seem to experience health problems or biochemical abnormalities.
A highly increased 25OHD/24,25(OH)2D ratio may be predictive of experiencing symptoms of hypercalcemia and/or hypercalciuria, irrespective of carriership status.
The incidence of nephrolithiasis and/or nephrocalcinosis may be increased in heterozygous carriers of CYP24A1 mutations.